Fortrea Holdings Inc. FTRE Clinical Services Segment — Pass through costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fortrea Holdings Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Fortrea Holdings Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fortrea Holdings Inc.'s clinical services segment — pass through costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fortrea Holdings Inc.'s clinical services segment — pass through costs?
- Fortrea Holdings Inc. (FTRE) reported clinical services segment — pass through costs of $229.9M in Q1 2026.
- How has Fortrea Holdings Inc.'s clinical services segment — pass through costs changed year-over-year?
- Fortrea Holdings Inc.'s clinical services segment — pass through costs decreased by 4.2% year-over-year, from $239.9M to $229.9M.
- What is the long-term trend for Fortrea Holdings Inc.'s clinical services segment — pass through costs?
- Over 3 years (2022 to 2025), Fortrea Holdings Inc.'s clinical services segment — pass through costs has grown at a 11.3% compound annual growth rate (CAGR), from $745.3M to $1.03B.
- What does clinical services segment — pass through costs mean?
- Refers to third-party expenses incurred by the segment on behalf of clients during clinical trials, such as investigator fees or laboratory costs, which are typically reimbursed. Monitoring these costs helps assess the segment's operational efficiency in managing external vendor relationships and client billing.